A Phase I study of patients with advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer

A Phase I study of ET-743 in combination with pegylated liposomal doxorubicin (PLD) in patients with advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223109

Enrollment

Registered

2016-02-22

Start date

2016-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with epithelial ovarian, primary peritoneal, or fallopian tube cancer

Interventions

investigational material(s) Generic name etc : ET-743, PLD INN of investigational material : Trabectedin, Doxorubicin Therapeutic category code : 42- Antineoplastic agents Dosage and Administration fo

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: - Patients who provided written informed consent to participate as subjects of this study - Patients who have histologically or cytologically proven epithelial ovarian, primary peritoneal, or fallopian tube cancer - Other

Exclusion criteria

Exclusion criteria: - Patients with severe diseases or medical conditions - Other

Design outcomes

Primary

Measure	Time frame
safety dose-limiting toxicity CTCAE Ver. 4.03	—

Secondary

Measure	Time frame
efficacy safety Safety, Efficacy CTCAE Ver. 4.03, RECIST Ver. 1.1	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026